Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients.
Sign Up to like & getrecommendations! Published in 2020 at "Neoplasma"
DOI: 10.4149/neo_2020_200128n93
Abstract: Pediatric refractory or relapsed acute lymphoblastic leukemia (ALL) poses unique therapeutic challenges, with novel immunotherapy approaches offering potential cure opportunities. In this frame, the use of Blinatumomab may induce durable remissions, serving as a successful… read more here.
Keywords: blinatumomab; acute lymphoblastic; use blinatumomab; pediatric relapsed ... See more keywords